Replimune Reports Fiscal Second Quarter 2027 Financial Results and Provides Corporate Update

Commercial deliveries began after quarter-end, while lower operating expenses helped narrow the quarterly loss.

Rhea-AI Summary

Replimune Group (REPL) reported a narrower fiscal second-quarter net loss of $57.1 million and outlined its TUDRIQEV commercial launch. Net loss was $83.1 million a year earlier; loss per share narrowed to $0.54 from $0.90. Research and development expenses fell to $34.4 million, while selling, general and administrative expenses fell to $21.9 million.

TUDRIQEV was first delivered to patients on October 6, 2026, and more than 15 institutions have prescribed it. It is available with nivolumab for adults with unresectable advanced cutaneous melanoma after progression on a PD-1-blocking regimen. Continued accelerated approval may depend on confirmatory clinical benefit. The IGNYTE-3 confirmatory trial and RP2 REVEAL trial are enrolling. Cash and cash equivalents were $307.8 million at September 30, following an equity offering and debt draw. Replimune expects its existing cash to fund operations for greater than twelve months from financial-statement issuance.

19 points · 0 major

PositiveiHow this balance works

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

How the balance worksHow Sentiment works

0 major · 7 points

Hollow bars mark forward-looking points. How the balance works

Positive

• Moderate pointAugust equity offering provided approximately $141.0 million in net proceeds. 11% of market cap
• Moderate pointSeptember tranche 4 debt draw provided $15.0 million in funding. 1.2% of market cap
• Moderate point. Forward-looking: it has not happened yet and may not happen.Replimune expects existing cash to fund operations for greater than twelve months from financial-statement issuance.
• Moderate pointQuarterly net loss narrowed to $57.121 million from $83.100 million; loss per share narrowed to $0.54 from $0.90.
• Minor pointTUDRIQEV first reached patients on October 6; more than 15 institutions have prescribed it.

14 minor points

• Minor pointTUDRIQEV launch preparation includes engagement with more than 70 percent of the initial 200 priority accounts.
• Minor pointTUDRIQEV payer policies cover use to label, alongside an NCCN guideline category 2A recommendation.
• Minor pointTUDRIQEV supply includes more than a year of inventory produced at Replimune’s manufacturing facility.
• Minor pointIGNYTE-3, the Phase 3 confirmatory trial of TUDRIQEV with nivolumab, is actively enrolling.
• Minor pointRP2 REVEAL, a registration-directed Phase 2/3 trial in metastatic uveal melanoma, is actively enrolling.
• Minor pointCash, cash equivalents and short-term investments rose to $307.833 million from $268.889 million at March 31, 2026.
• Minor pointQuarterly research and development expenses fell to $34.365 million from $57.877 million a year earlier.
• Minor pointQuarterly selling, general and administrative expenses fell to $21.916 million from $26.414 million a year earlier.
• Minor pointSix-month net loss narrowed to $126.887 million from $169.793 million; loss per share narrowed to $1.26 from $1.85.
• Minor pointSix-month research and development expenses fell to $83.644 million from $115.721 million a year earlier.
• Minor pointSix-month selling, general and administrative expenses fell to $40.885 million from $58.994 million a year earlier.
• Minor pointWorking capital increased to $278.482 million from $220.891 million at March 31, 2026.
• Minor pointTotal assets increased to $373.940 million from $332.388 million at March 31, 2026.
• Minor pointStockholders’ equity increased to $204.778 million from $166.160 million at March 31, 2026.

Negative

• Moderate point. Forward-looking: it has not happened yet and may not happen.TUDRIQEV continued accelerated approval may be contingent on verification of clinical benefit in confirmatory trials.
• Moderate pointAugust offering issued common stock and pre-funded warrants, adding dilution exposure for existing holders.
• Moderate pointSeptember tranche 4 draw added $15.0 million in long-term debt. 1.2% of market cap
• Minor pointQuarterly debt interest expense rose to $2.523 million from $1.488 million a year earlier.
• Minor pointSix-month debt interest expense rose to $5.104 million from $2.963 million a year earlier.

2 minor points

• Minor pointQuarterly investment income fell to $1.880 million from $3.696 million a year earlier.
• Minor pointSix-month investment income fell to $3.840 million from $8.411 million a year earlier.

News Explained

The August offering raised approximately $141.0 million net through common stock and pre-funded warrants; issuing shares reduces existing holders’ ownership percentages, while warrant exercise can add further shares, but the release gives no share or warrant counts to size that effect.

Argus 15 min delay 127 alerts

-1.49% vs previous close $15.82 last price 4.0x rel. volume Open Argus

Details

Market Reaction – REPL

$12.15 – $16.75 Day Range

$1.49B Mkt Cap at Last Price

On Oct 28, the day this news came out, the latest delayed price for REPL is 1.49% below the previous close. Our momentum scanner has recorded 127 alerts for this stock so far that day. The latest delayed price is $15.82. Relative volume is very high at 4.0x the average.

Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.

Key Figures

Cash and cash equivalents: $307.8 million Cash runway: Greater than twelve months Net loss: $57.1 million +3 more

Cash and cash equivalents

$307.8 million

As of September 30, 2026

Cash runway

Greater than twelve months

Company expectation from issuance of the financial statements

Net loss

$57.1 million

Fiscal Q2 ended September 30, 2026; compared with $83.1 million in fiscal Q2 2025

R&D expenses

$34.4 million

Fiscal Q2 ended September 30, 2026; compared with $57.9 million in fiscal Q2 2025

Selling, general and administrative expenses

$21.9 million

Fiscal Q2 ended September 30, 2026; compared with $26.4 million in fiscal Q2 2025

Net proceeds from common stock and pre-funded warrants

Approximately $141.0 million

August 2026 offering

Previous Earnings Reports

1 past event · Latest: Nov 06

Same Type 1 event

1. Nov 06

   Earnings report

   24h Move

   -0.9%

   Fiscal Q2 2026 reported an $83.1M net loss, the year-over-year comparator in this release.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

accelerated approval, objective response rate, overall survival, progression free survival, +2 more

6 terms

accelerated approval regulatory

"This indication is approved under accelerated approval based on objective response rate"

Accelerated approval is a process that allows new medical treatments to be approved more quickly than usual if they address serious or life-threatening conditions and show promising early results. For investors, it signals that a treatment may reach the market sooner, potentially boosting a company's prospects, but it also involves some uncertainty since full evidence of effectiveness is still being gathered.

objective response rate medical

"accelerated approval based on objective response rate (ORR) and duration of response"

The objective response rate (ORR) is the percentage of patients in a clinical trial whose tumors measurably shrink or disappear according to preset rules. Investors use it as a quick, objective signal of a drug’s ability to produce a clear treatment effect—like counting how many plants visibly respond after applying a new fertilizer—and higher ORR can improve odds of regulatory approval, commercial success, and company valuation.

overall survival medical

"The primary endpoint is overall survival"

Overall survival is the average or median length of time patients remain alive after starting a treatment or entering a clinical study, measured regardless of cause of death. Investors care because it is a clear, hard measure of a therapy’s real-world benefit — like timing how long a new battery actually runs — and strong improvements in overall survival can drive regulatory approval, market adoption and revenue potential.

progression free survival medical

"key secondary endpoints are progression free survival and overall response rate"

Progression free survival is the length of time during and after a treatment when a disease, such as cancer, does not get worse or spread. It is an important measure because longer periods of stability can indicate that a treatment is effectively controlling the condition. For investors, it provides insight into the potential durability and success of a therapy or medication.

pre-funded warrants financial

"offering of common stock and pre-funded warrants in August 2026"

Pre-funded warrants are financial instruments that give investors the right to purchase a company's stock at a set price, but with most or all of the purchase price paid upfront. They function like a coupon or gift card for stock, allowing investors to buy shares later at a fixed price, which can be beneficial if they want to avoid future price increases. This makes them important for investors seeking flexibility and certainty in their investment plans.

stock-based compensation financial

"included $4.9 million in stock-based compensation expenses"

Stock-based compensation is when a company pays employees, directors or consultants with shares or the right to buy shares instead of or in addition to cash. It matters to investors because issuing stock or options spreads ownership thinner (like cutting a pie into more slices), which can reduce each existing share’s claim on profits and can also change reported earnings; investors watch it to assess true cost of running the business and how management is incentivized.

View in glossary

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

TUDRIQEV first delivered to patients for advanced melanoma on October 6th

More than 15 institutions have prescribed TUDRIQEV

Management will host a webcast today at 8:00 a.m. ET

WOBURN, Mass., Oct. 28, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a commercial stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced financial results for the fiscal second quarter ended September 30, 2026 and provided a business update.

In early October, the Company announced that TUDRIQEV (vusolimogene oderparepvec-wtpg), previously referred to as RP1, is now commercially available in the United States for use in combination with nivolumab for the treatment of adults with advanced melanoma. Healthcare providers began ordering TUDRIQEV for next day delivery immediately upon availability. The Company has more than a year of inventory on hand, produced at its in-house manufacturing facility.

“Melanoma takes nearly 8,500 lives in the U.S. every year, and for patients whose disease progresses after anti-PD-1 therapy, treatment options have been limited. TUDRIQEV is now available to patients in urgent need,” said Sushil Patel, Ph.D., CEO of Replimune. “The response from physicians has been enthusiastic and both oncologists and interventional radiologists are eager to bring TUDRIQEV into their practices. They value the broad label that lets them treat patients immediately after progression on a PD-1 based therapy. We are focused on reaching as many of these patients as possible.”

Program Highlights & Milestones

TUDRIQEV™ (vusolimogene oderparepvec-wtpg)

• Early launch off to a positive start. The Company has actively engaged with more than 70 percent of its initial 200 priority accounts to establish workflows and enable TUDRIQEV adoption. Leading melanoma institutions have rapidly placed TUDRIQEV on formulary and have started treating patients.
• Broad label supports use across a wide range of patients. TUDRIQEV is indicated in combination with nivolumab after progression on a PD-1-blocking antibody-based regimen, with no requirement for prior BRAF treatment, and can be injected into superficial, deep and visceral lesions, including lung and liver. Patients can be retreated if clinically appropriate.
• Rapid and broad payer coverage facilitated by NCCN guideline inclusion. Multiple payer policies have been published covering TUDRIQEV to label. TUDRIQEV has been listed in the NCCN Clinical Practice Guidelines in Oncology as a category 2A recommendation.
• IGNYTE-3 confirmatory study remains on track. The global Phase 3 trial assessing TUDRIQEV in combination with nivolumab versus physician’s choice in patients with advanced melanoma who have progressed on anti-PD-1 and anti-CTLA-4 therapies or are ineligible for anti-CTLA-4 treatment is actively enrolling. The primary endpoint is overall survival, and key secondary endpoints are progression free survival and overall response rate.

RP2

• REVEAL Study: The registration-directed Phase 2/3 trial of RP2 in metastatic uveal melanoma is actively enrolling. The trial is evaluating RP2 in combination with nivolumab versus ipilimumab in combination with nivolumab. The primary endpoints of the trial are overall survival and progression free survival, and key secondary endpoints are overall response rate and disease control rate.
  

Financial Highlights

• Cash Position: As of September 30, 2026, cash and cash equivalents were $307.8 million, as compared to cash, cash equivalents and short-term investments of $268.9 million as of fiscal year ended March 31, 2026. The increase in cash balance was a result of approximately net $141.0 million in proceeds from the Company's offering of common stock and pre-funded warrants in August 2026, as well as $15.0 million in proceeds from long-term debt from the initial draw down on tranche 4 in September 2026, partially offset by cash burn related to operating activities in advancing the company’s clinical development plans.
  
  We expect that our existing cash and cash equivalents will enable us to fund operations for greater than twelve months from the issuance of the condensed consolidated financial statements, which includes the commercialization of TUDRIQEV in advanced melanoma and for working capital and general corporate purposes.
  
  
• R&D Expenses: Research and development expenses were $34.4 million for the fiscal second quarter ended September 30, 2026, and $57.9 million for the fiscal second quarter ended September 30, 2025. This decrease was primarily due to a decrease in personnel related and other costs, as well as a decrease in direct research costs relating to the IGNYTE, ARTACUS and CERPASS studies. Research and development expenses included $4.9 million in stock-based compensation expenses for the fiscal second quarter ended September 30, 2026.
  
  
• S,G&A Expenses: Selling, general and administrative expenses were $21.9 million for the fiscal second quarter ended September 30, 2026, as compared to $26.4 million for the fiscal second quarter ended September 30, 2025. Selling, general and administrative expenses included $5.7 million in stock-based compensation expenses for the fiscal second quarter ended September 30, 2026.
  
  
• Net Loss: Net loss was $57.1 million for the fiscal second quarter ended September 30, 2026 and $83.1 million for the fiscal second quarter ended September 30, 2025.

About TUDRIQEV™ (vusolimogene oderparepvec-wtpg)

TUDRIQEV is a genetically modified herpes simplex virus type 1 (HSV-1) oncolytic viral therapy that encodes a fusogenic glycoprotein derived from gibbon ape leukemia virus with the R sequence deleted (GALV-GP-R–) and human granulocyte macrophage colony-stimulating factor (GM-CSF). The genes encoding the HSV-1 neurovirulence factor ICP34.5 and the ICP47 inhibitor of antigen presentation are deleted. TUDRIQEV preferentially replicates within tumors, leading to tumor lysis and release of tumor and viral antigens. In combination with nivolumab, TUDRIQEV may promote an anti-tumor immune response in the anti-PD-1-resistant setting. For more information, visit Tudriqev.com.

INDICATION

TUDRIQEV™ is indicated in combination with nivolumab for the treatment of adult patients with unresectable advanced cutaneous melanoma who experienced disease progression with a programmed death receptor-1 (PD-1)-blocking antibody-based regimen.

This indication is approved under accelerated approval based on objective response rate (ORR) and duration of response. Continued approval for this indication may be contingent upon verification of clinical benefit in a confirmatory trial(s).

IMPORTANT SAFETY INFORMATION

Warnings and Precautions
Accidental exposure of TUDRIQEV: Healthcare providers, caregivers, close contacts, pregnant women, newborns, and patients should avoid direct contact with injected tumors, dressings, or bodily fluids of patients. Herpetic infection or reactivation: Patients with suspected herpetic infections should contact their healthcare provider for assessment and antiviral treatment of the suspected herpetic infection as clinically warranted. Injection procedure complications: Complications related to injection procedure have occurred, including hemorrhage, infection, and visceral injury. Patients should be monitored for signs and symptoms of visceral injury (eg, pneumothorax) during and after TUDRIQEV administration and managed according to clinical practice. Immune-mediated events: In clinical studies, immune-mediated events, including colitis, hepatitis, myocarditis, neuropathy, capillary leak syndrome, dermatitis, and vitiligo have been reported in patients treated with TUDRIQEV and nivolumab.

Adverse Reactions
Most common non-laboratory adverse reactions reported in more than 10% of patients were fatigue, pyrexia, infections, chills, musculoskeletal pain, nausea, diarrhea, injection site reaction, headache, cough, influenza like illness, rash, vomiting, pruritus, arthralgia, constipation, decreased appetite, dizziness, dyspnea, hemorrhage, edema, and abdominal pain. Serious adverse reactions occurring in >1% patients include pleural effusion (n=3), acute kidney injury (n=2), arthralgia (n=2), atrial fibrillation (n=2), atrial flutter (n=2), cancer pain (n=2), hypophysitis (n=2), immune-mediated enterocolitis (n=2), pyrexia (n=2), sepsis (n=2), urinary tract infection (n=2), and myocardial infarction (n=2). Serious adverse reactions leading to death include myocardial infarction (n=1) and multiple organ dysfunction (n=1).

Drug Interactions
Patients receiving systemic antiviral treatment for herpetic infection should delay TUDRIQEV treatment for 72 hours after completion of antiviral therapy.

Special Populations
Advise females and males of reproductive potential to use effective contraception during treatment with TUDRIQEV and for 90 days after the last dose.

About RP2

RP2 is based on a proprietary strain of herpes simplex virus engineered and genetically armed with a fusogenic protein (GALV-GP R-) and GM-CSF intended to maximize tumor killing potency, the immunogenicity of tumor cell death and the activation of a systemic anti-tumor immune response. RP2 additionally expresses an anti-CTLA-4 antibody-like molecule, as well as GALV-GP R- and GM-CSF. RP2 is intended to provide targeted and potent delivery of these proteins to the sites of immune response initiation in the tumor and draining lymph nodes, with the goal of focusing systemic-immune-based efficacy on tumors and limiting off-target toxicity.

About Replimune

Replimune Group, Inc., headquartered in Woburn, MA, was founded in 2015 with the mission to transform cancer treatment by pioneering the development of novel oncolytic immunotherapies. Replimune’s proprietary RPx platform is based on a potent HSV-1 backbone intended to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The RPx platform is intended to ignite local activity consisting of direct selective virus-mediated killing of the tumor resulting in the release of tumor derived antigens and altering of the tumor microenvironment to then activate a strong and durable systemic response. The RPx product candidates are expected to be synergistic with most established and experimental cancer treatment modalities, leading to the versatility to be developed alone or combined with a variety of other treatment options. For more information, please visit www.replimune.com. 

Forward Looking Statements
This press release contains forward looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding clinical trials, clinical studies and other clinical work (including the funding therefor, anticipated patient enrollment, safety data, study data, trial outcomes, timing or associated costs, sufficiency of any resulting data), regulatory applications and related submission contents and timelines, the timelines or outcomes related to litigation, including any rehearings or appeals of decisions in any such proceedings, and our expectations about our cash runway, our ability to execute on our strategic or financial initiatives, our estimates regarding future expenses, capital requirements and needs for additional financing, and potential commercial viability, and potential reimbursement and utilization of TUDRIQEV involve significant risks and uncertainties and actual results could differ materially from those expressed or implied herein. Our ability to maintain TUDRIQEV’s accelerated approval and to continue commercialization of TUDRIQEV may be contingent on verification of clinical benefit in a confirmatory trial(s). Other forward looking statements may be identified by words such as “could,” “expects,” “intends,” “may,” “plans,” “potential,” “should,” “will,” “would,” or similar expressions and the negatives of those terms. Forward-looking statements are not promises or guarantees of future performance and are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in such forward-looking statements. These factors include risks related to our limited experience in commercializing products for sale, our ability to successfully verify the clinical benefit of TUDRIQEV in our ongoing confirmatory Phase 3 trial, IGNYTE-3, our ability to meet our product manufacturing goal, the timing and scope of future regulatory approvals, the availability of combination therapies needed to conduct our clinical trials, changes in laws and regulations to which we are subject, competitive pressures, our ability to identify additional product candidates, the impact of political and global macro factors and military conflicts, and other risks as may be detailed from time to time in our Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q and other reports we file with the Securities and Exchange Commission. Our actual results could differ materially from the results described in or implied by such forward-looking statements. Forward-looking statements speak only as of the date hereof, and, except as required by law, we undertake no obligation to update or revise these forward-looking statements.

Investor Inquiries
Chris Brinzey
ICR Healthcare
339.970.2843
chris.brinzey@icrhealthcare.com 

Media Inquiries
Arleen Goldenberg
Replimune
917.548.1582
media@replimune.com 

Replimune Group, Inc. Condensed Consolidated Statements of Operations (Amounts in thousands, except share and per share amounts) (Unaudited)
	Three Months Ended September 30,								Six Months Ended September 30,
		2026				2025				2026				2025
Operating expenses:
Research and development	$	34,365			$	57,877			$	83,644			$	115,721
Selling, general and administrative		21,916				26,414				40,885				58,994
Total operating expenses		56,281				84,291				124,529				174,715
Loss from operations		(56,281	)			(84,291	)			(124,529	)			(174,715	)
Other income (expense):
Research and development incentives		238				377				534				797
Investment income		1,880				3,696				3,840				8,411
Interest expense on finance lease liability		(502	)			(518	)			(1,007	)			(1,039	)
Interest expense on debt obligations		(2,523	)			(1,488	)			(5,104	)			(2,963	)
Other income (expense), net		67				(876	)			(621	)			(284	)
Total other (expense) income, net		(840	)			1,191				(2,358	)			4,922
Net loss	$	(57,121	)		$	(83,100	)		$	(126,887	)		$	(169,793	)
Net loss per common share, basic and diluted	$	(0.54	)		$	(0.90	)		$	(1.26	)		$	(1.85	)
Weighted average common shares outstanding, basic and diluted		105,176,101				91,915,769				101,042,985				91,717,076

Replimune Group, Inc. Condensed Consolidated Balance Sheets (Amounts In thousands, except share and per share amounts) (Unaudited)
	September 30, 2026			March 31, 2026
	(in thousands)
Consolidated Balance Sheet Data:
Cash, cash equivalents and short-term investments	$	307,833		$	268,889
Working capital		278,482			220,891
Total assets		373,940			332,388
Total stockholders' equity		204,778			166,160

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What were Replimune’s fiscal second-quarter 2027 financial results?

Replimune reported a $57.121 million net loss, or $0.54 per share, for the three months ended September 30, 2026. A year earlier, net loss was $83.100 million, or $0.90 per share. Research and development expenses and selling, general and administrative expenses both declined.

When did Replimune begin delivering TUDRIQEV to patients?

TUDRIQEV was first delivered to patients on October 6, 2026. More than 15 institutions have prescribed it. It is commercially available in the United States with nivolumab for adults with unresectable advanced cutaneous melanoma whose disease progressed on a PD-1-blocking antibody-based regimen.

What is Replimune’s IGNYTE-3 confirmatory trial measuring?

IGNYTE-3 measures overall survival as its primary endpoint, comparing TUDRIQEV plus nivolumab with physician’s choice. The actively enrolling Phase 3 trial includes advanced melanoma patients who progressed on anti-PD-1 and anti-CTLA-4 therapies or are ineligible for anti-CTLA-4 treatment. Secondary endpoints include progression-free survival and overall response rate.

What treatments are being compared in Replimune’s RP2 REVEAL trial?

RP2 REVEAL compares RP2 plus nivolumab with ipilimumab plus nivolumab in metastatic uveal melanoma. The registration-directed Phase 2/3 trial is actively enrolling. Its primary endpoints are overall survival and progression-free survival; secondary endpoints include overall response rate and disease control rate.